Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma.

Abstract

PURPOSE:

A phase II study of temsirolimus was conducted in children and adolescents with high-grade glioma, neuroblastoma or rhabdomyosarcoma.

PATIENTS AND METHODS:

Temsirolimus 75 mg/m(2) was administered once weekly until disease progression or intolerance. Using the Simon 2-stage design, further enrolment in each disease cohort required ≥ 2 objective responses within the first 12 weeks for the first 12 evaluable patients (those who received ≥ 3 temsirolimus doses).

RESULTS:

Fifty-two heavily pretreated patients with relapsed (12%) or refractory (88%) disease, median age 8 years (range 1-21 years), were enroled and treated. One patient with neuroblastoma achieved confirmed partial response within the first 12 weeks; thus, none of the 3 cohorts met the criterion for continued enrolment. Disease stabilisation at week 12 was observed in 7 of 17 patients (41%) with high-grade glioma (5 diffuse pontine gliomas, 1 glioblastoma multiforme and 1 anaplastic astrocytoma), 6 of 19 (32%) with neuroblastoma and 1 of 16 (6%) with rhabdomyosarcoma (partial response confirmed at week 18). In the three cohorts, median duration of stable disease or better was 128, 663 and 75 d, respectively. The most common treatment-related adverse events were thrombocytopaenia, hyperlipidaemia and aesthenia. Pharmacokinetic findings were similar to those observed in adults.

CONCLUSIONS:

Temsirolimus administered weekly at the dose of 75 mg/m(2) did not meet the primary objective efficacy threshold in children with high-grade glioma, neuroblastoma or rhabdomyosarcoma; however, meaningful prolonged stable disease merits further evaluation in combination therapy.

• Authors: Birgit Geoerger, Mark W Kieran, Stephan Grupp, Danuta Perek, Jill Clancy, Mizue Krygowski, Revathi Ananthakrishnan, Joseph P Boni, Anna Berkenblit, Sheri L Spunt
• Journal: European journal of cancer (Oxford, England : 1990) (Eur J Cancer) Vol. 48 Issue 2 Pg. 253-62 (Jan 2012) ISSN: 1879-0852 [Electronic] England
• PMID: 22033322 (Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2011 Elsevier Ltd. All rights reserved.

Chemical References

• Antineoplastic Agents
• temsirolimus
• Sirolimus

Topics

• Adolescent
• Adult
• Antineoplastic Agents (pharmacokinetics, therapeutic use)
• Brain Neoplasms (drug therapy)
• Child
• Child, Preschool
• Cohort Studies
• Disease Progression
• Female
• Glioma (drug therapy)
• Humans
• Infusions, Intravenous
• Male
• Neuroblastoma (drug therapy)
• Rhabdomyosarcoma (drug therapy)
• Sirolimus (analogs & derivatives, pharmacokinetics, therapeutic use)